Quick Takeaways
- Polar Capital Holdings Plc filed SCHEDULE 13G for ENLIVEN THERAPEUTICS, INC. Common Stock, $0.001 par value per share (ELVN).
- Disclosed ownership: 5.2%.
- Date of event: 30 Jun 2025.
Polar Capital Holdings Plc - 30 Jun 2025 SCHEDULE 13G Report for ENLIVEN THERAPEUTICS, INC. Common Stock, $0.001 par value per share (ELVN)
- Filing Manager
- Polar Capital Holdings Plc
- Reporting Manager
- Polar Capital Holdings Plc
- Symbol
- ELVN
- Shares outstanding
- 49,069,265 shares
- Disclosed Ownership
- 2,536,881 shares
- Ownership
- 5.2%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Aug 2025, 08:01:03 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 14 Feb 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Polar Capital Holdings Plc disclosed 5.2% ownership in ENLIVEN THERAPEUTICS, INC. Common Stock, $0.001 par value per share (ELVN) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 14 Feb 2025.
- Current filing was accepted on 14 Aug 2025, 08:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 5.2% | 2,536,881 | 2,536,881 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer | |
| Polar Capital LLP | 5.2% | 2,536,881 | 2,536,881 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer | |
| Polar Capital Funds PLC - Biotechnology Fund | 5.2% | 2,536,881 | 2,536,881 | 0 | /s/ Nicholas Farren | Nicholas Farren - Chief Operating Officer |